Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 58

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 58
---
 Q3 2025 Form 10-Q  |  13

Disaggregated RevenueThe following table represents disaggregated net product sales in the periods presented as follows (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Net product sales:   EXPAREL$139,902 $132,004 $419,348 $401,286    ZILRETTA28,982 28,420 83,654 84,966    iovera°6,465 5,655 17,176 16,359    Bupivacaine liposome injectable suspension2,691 1,643 5,803 7,322       Total net product sales$178,040 $167,722 $525,981 $509,933 

NOTE 5—INVENTORIES

The components of inventories, net are as follows (in thousands):September 30,December 31,20252024Raw materials$46,428 $50,800 Work-in-process18,840 27,384 Finished goods92,412 47,098      Total$157,680 $125,282 

In July 2025, the Company announced it decommissioned its 45-liter EXPAREL batch manufacturing suite located at its Science Center Campus in San Diego, California, and reduced its workforce accordingly. As a result, the Company reserved $1.0 million of raw materials related to that equipment during the nine months ended September 30, 2025. 

NOTE 6—FIXED ASSETS

Fixed assets, net, summarized by major category, consist of the following (in thousands):September 30,December 31,20252024Machinery and equipment$163,980 $160,643 Leasehold improvements76,343 86,034 Computer equipment and software25,814 23,473 Office furniture and equipment2,131 1,952 Construction in progress11,785 27,996         Total280,053 300,098 Less: accumulated depreciation(132,665)(132,929)        Fixed assets, net$147,388 $167,169 For the three months ended September 30, 2025 and 2024, depreciation expense was $6.9 million and $6.0 million, respectively. For